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The impact of pharmacogenetic variants of cytochrome P450 2C19 (CYP2C19) on
clopidogrel-mediated effects on platelet inhibition, inflammatory response and endothelial
function, as well as risk of major adverse cardiovascular events (MACE), in coronary heart
patients undergoing percutaneous coronary intervention (PCI) was investigated. To this
end, we assessed the residual platelet aggregation rate (RPA), maximal aggregation rate
(MAR) and plasma levels of sCD40L, sP-selectin, MMP-9, sVCAM-1 and sE-selectin
after 24 h of PCI in 559 patients treated with clopidogrel and followed up for 1
year for evidence of MACE. CYP2C19 ∗2 and ∗3 variants were identified using a
clopidogrel-sensitive gene detection kit. Our results showed higher RPA and MAR as
well as increased sE-selectin, sCD40L, sP-selectin, MMP-9, and sVCAM-1 levels in
CYP2C19 intermediate metabolizer (IM, CYP2C19∗1/∗2, or ∗1/∗3), poor metabolizer
(PM, CYP2C19∗2/∗2, ∗2/∗3, or ∗3/∗3) and combined IM+PM groups, relative to those
in extensive metabolizers (EM, CYP2C19∗1/∗1). In total, 519 patients completed 1
year of follow-up, among which 69 (13.3%) experienced MACE. The risk of MACE in
CYP2C19 IM+PM patients was 2.664 times higher than that in CYP2C19 EM patients
(OR = 2.664 (1.397–5.193), P = 0.004). The data suggest that CYP2C19∗2 and ∗3
variants modulate the drug efficacy of clopidogrel in coronary heart patients undergoing
PCI and further enhance the risk of MACE. Accordingly, CYP2C19 pharmacogenetic
profiling may be beneficial for coronary heart patients undergoing PCI to predict the
efficacy of treatment with clopidogrel. We propose that IM and PM patients should
benefit from treatment with higher clopidogrel doses to improve efficacy and reduce the
incidence of MACE.
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INTRODUCTION
Owing to dietary and lifestyle changes, the number of coronary
heart disease (CHD) patients worldwide has increased over
the years. Percutaneous coronary intervention (PCI) is one of
the most significant developments in the treatment of CHD.
However, stent thrombosis (ST) is a major complication affecting
the efficacy of PCI. Currently, anti-platelet drugs, such as
clopidogrel and aspirin, are used to prevent the occurrence of
ST after PCI (Stone et al., 2013). Post-operative joint use of
clopidogrel and aspirin antiplatelet therapy has been shown to
reduce ST, death, myocardial infarction and other major adverse
cardiovascular events (MACE), and has rapidly become standard
treatment (Steinhubl et al., 2002; Han et al., 2015). However,
a number of patients taking conventional doses of clopidogrel
continue to experience severe coronary ischemic events (Müller
et al., 2003; Stone et al., 2013). The rate of clopidogrel resistance
is reported to range from 4.2 to 27.8% (Järemo et al., 2002;
Serebruany et al., 2005), implying individual differences in the
antiplatelet efficacy of clopidogrel.
Several factors affect the antiplatelet activity of clopidogrel,
including inter-patient compliance, age, diabetes, smoking, and
drug interactions (Sabaté et al., 2015). Although the efficacy
of clopidogrel is linked to several enzymes, transporters and
acceptors, such as CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1,
and P2Y12, the most important factors suggested to be associated
with low response to the drug are CYP2C19∗2 and CYP2C19∗3
variants (Nagashima et al., 2013; Jiang et al., 2015; Sabaté et al.,
2015; Ma et al., 2016). The impact of CYP2C19 variants on risk
of MACE is controversial (Mega et al., 2009, 2010b; Bauer et al.,
2011; Han et al., 2015). A systematic review and meta-analysis by
Bauer et al. (2011) revealed no substantial or consistent influence
of CYP2C19 variants on the clinical efficacy of clopidogrel
and risk of MACE. In contrast, the groups of Mega and Han
reported significantly increased risk of MACE in association with
CYP2C19∗2 and ∗3 variants (Mega et al., 2010b; Han et al., 2015;
Khalil et al., 2016).
Clopidogrel, an irreversible inhibitor of the adenosine
diphosphate (ADP) platelet receptor, P2Y12, is widely used to
prevent thromboembolic events in patients (Wei et al., 2015). The
platelet function test is usually employed to detect the antiplatelet
efficacy of clopidogrel. ADP-induced optical turbidity has been
the "gold standard" to evaluate the efficacy of clopidogrel for
several decades (Steinhubl et al., 2002). Clopidogrel is reported
to block the platelet ADP receptor to inhibit platelet aggregation,
which reduces the expression and release of plasma-soluble
CD40 ligand (sCD40L) and P-selectin, from platelets, preventing
further platelet activation (Li et al., 2015; Obradovic et al., 2015).
SCD40L is mainly generated by cleavage of CD40L from the
surface of activated platelets, and is therefore considered a platelet
activationmarker (Gremmel et al., 2015; Li et al., 2015). P selectin
is mainly located in α-particles of platelets and stick tubular
bodies (Weibel-Palade) of endothelial cells (Kaufmann et al.,
2013). During platelet activation and endothelial damage, the
protein is rapidly expressed on the cell surface, thereby mediating
leukocyte, platelet, and endothelial cell adhesion (Kaufmann
et al., 2013).
The mechanism underlying ST after PCI is complex. Anti-
platelet drugs only act on a specific part of this complex network
(Antonino et al., 2009). Chronic inflammation and endothelial
damage are important steps in the pathogenesis of thrombosis
after PCI (Antonino et al., 2009; Willoughby et al., 2014).
Clopidogrel exerts not only anti-inflammatory activity but also
protective effects on the vascular endothelium (Liu et al., 2012;
Willoughby et al., 2014). The drug protects the endothelium
by hindering the expression of vascular cell adhesion molecule-
1 (VCAM-1) that is induced by a variety of cytokines (Yang
et al., 2016). E-selectin, a cell adhesion molecule located on
the vascular endothelial cell surface, is the first to be expressed
in the inflammatory reaction, in turn causing aggravation of
endothelial damage, enhanced inflammation, plaque rupture and
thrombosis (Smadja et al., 2012). Increased levels of the adhesion
molecule, gelatinase matrix metalloproteinase-9 (MMP-9), an
inflammatory marker, can induce plaque rupture, resulting in
thrombosis (Sternberg et al., 2016).
Considering this background, we aimed to investigate
whether CYP2C19 variants are involved in (1) clopidogrel-
mediated platelet effects, (2) clopidogrel-mediated inflammatory
endothelial effects, and (3) risk of MACE.
METHODS
Patients and Study Design
Patients were enrolled from Fujian Provincial Hospital between
March 2012 and March 2014. The ethics committee of the
hospital approved the study and all patients provided written
informed consent. Procedures were carried out in accordance
with the approved guidelines. This prospective study was
designed to determine the effects of CYP2C19 variants on platelet
reactivity, inflammatory and endothelial biomarkers and 1-year
clinical outcomes in CHD patients undergoing PCI. Patients
were eligible for study enrollment in the cases where (1) ages
were higher than 18 and (2) they were diagnosed with CHD
using coronary angiography and successfully treated with PCI.
Exclusion criteria were as follows: (1) aspirin, clopidogrel and
contrast agent allergy, (2) severe diseases, such as tumors
and bleeding disorders, (3) hemodynamic instability (systolic
blood pressure <90mmHg and/or diastolic blood pressure <50
mmHg), severe ventricular dysfunction (LVEF <40%), (4) severe
liver and kidney dysfunction, (5) blood disease or bleeding
diathesis, platelet count <100× 109/L and hematocrit <30%.
Platelet Function Test
After 24 h of PCI, 3 ml peripheral blood samples were collected
and mixed with 3.8% trisodium citrate, and platelet aggregation
was determined via the turbidimetric method in 2 h with a
four-channel light transmission aggregometer (LBY-BJ4; Precil,
Beijing, China). Platelet aggregation was stimulated with 5
µmol/L adenosinediphosphate (ADP). After agonist stimulation,
the degree of light transmission was monitored. Results were
recorded as light transmission at maximal aggregation. The
platelet aggregation rate was recorded as a curve for 5 min and
expressed as residual platelet aggregation rate (RPA).
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After 24 h of PCI, creatinine (Cr), lipids (TC, TG, HDL-
c, LDL-c), platelet count (PLT), RPA, and fibrinogen (FIB)
levels were tested in the hospital laboratory and plasma levels
of sCD40L, sP-selectin, MMP-9, sVCAM-1, and sE-selectin
were assessed via enzyme-linked immunosorbent assay (ELISA)
(HUAMEI, Wuhan, China) according to the manufacturer’s
instructions.
PCI and Clopidogrel Treatment
PCI was performed in accordance with the standard of care.
All patients were administered 300mg clopidogrel and 40mg
atorvastatin prior to the operation. The operator decided on
the choice of anticoagulant and the use of glycoprotein IIb/IIIa
inhibitor (tirofiban), as well as the type of stent. After PCI,
patients were treated with 100mg/day aspirin indefinitely and 75
mg/day clopidogrel for 1 year. We defined the success of PCI
as follows: (1) achievement of complete revascularization and
residual stenosis of <20% in target vessels of patients, (2) level 3
TIMI blood flow, (3) partial or complete remission of symptoms
of myocardial ischemia, and (4) no serious complications during
hospitalization (such as acute myocardial infarction, urgent
target lesion revascularization or death).
Genotype Analysis
CYP2C19 genotypes were identified using the clopidogrel-
sensitive gene detection kit (BAIO company, Shanghai, China).
DNA was extracted from whole peripheral blood, followed
by stepwise evaluation involving single-base primer extension,
PCR amplification chip spotting, mass spectrometry, DNA
microarray and analysis of data with software to obtain CYP2C19
genotypes. All steps were performed in strict accordance with
the BAIO genetic analyzer manual instructions. According to
the CYP2C19∗1, ∗2, ∗3 genotypes, patients carrying ∗1/∗1 were
grouped as extensive metabolizers (EM), ∗1/∗2 or ∗1/∗3 as
intermediate metabolizers (IM), and ∗2/∗2, ∗2/∗3 or ∗3/∗3 as poor
metabolizers (PM).
Clinical Endpoints
The clinical endpoints include the following MACE: cardiac
death, myocardial infarction, and unstable angina. Cardiac death
was defined as any death due to cardiovascular causes or not
clearly attributable to non-cardiovascular causes. Myocardial
infarction was defined as recent ischemic symptoms with
ST-segment elevation or depression and abnormally elevated
troponin. Unstable angina was defined as resting onset, duration
greater than or equal to 20min or more severe and longer
duration of angina than before and higher frequency of onset.
Diagnosis was performed during hospitalization according to
serum creatine kinase levels, electrocardiogram findings and
other indicators.
Statistical Analysis
Statistical analysis was carried out using SPSS software
(version 11.0 for Windows; SPSS, Chicago, IL). Continuous
data, presented as median and interquartile range, were
compared using Kruskal-Wallis one-way analysis of variance
or Mann-Whitney U test. Measurement data following normal
distribution were expressed as means ± standard deviation
(x ± s) and compared using t-test or univariate analysis of
variance (ANOVA). Categorical variables were compared with
the chi-square or Fisher exact test, as appropriate. Time-to-
event outcomes were analyzed via Kaplan-Meier analysis and
differences compared with the log-rank test. Logistic regression
analysis was performed to assess independent predictors of
MACE. P < 0.05 were considered statistically significant.
RESULTS
Study Population
A flow diagram of the study is shown in Figure 1. A total
of 612 patients provided written informed consent. Based on
inclusion criteria, 559 of these patients were enrolled for 1-
year follow-up. Owing to loss to follow-up and poor medication
compliance, 40 patients were further excluded, leading to a final
total of 519 study participants. The follow-up rate was 95.3%.
Clinical characteristics of patients are presented in Table 1.
According to CYP2C19 genotype, 181, 253, and 85 patients
were grouped as EM, IM, and PM, respectively, for further
study. Comparison of clinical characteristics among the three
groups disclosed no significant differences in age, gender, body
mass index (BMI), CHD risk factors (hypertension, diabetes,
smoking) and previous history of myocardial infarction (P >
0.05). Levels of lipids, creatinine, platelet count and fibrinogen
were comparable among the three groups (P > 0.05). Differences
in usage of clinical medicines, including ACEI/ARB, β-blockers,
CCB, statins, PPI, and tirofiban (P > 0.05) were not statistically
significant. Moreover, left main coronary artery lesions, vascular
lesions (≧3), frame lengths and bracket numbers were similar
among the three groups (P > 0.05).
Effects of CYP2C19 Metabolizers on the
Drug Efficacy of Clopidogrel
After 24 h of PCI, we measured levels of RPA, MAR, sE-selectin,
sCD40L, sP-selectin, MMP-9, and sVCAM-1 in all patients.
Significant differences were observed among the three groups
FIGURE 1 | Flow diagram of the study.
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TABLE 1 | Clinical characteristics of clopidogrel-treated patients with various genotypes of CYP2C19 after PCI.
Parameters Patient numbers (N = 519) CYP2C19 genotypes P-value
EM (N = 181) IM (N = 253) PM (N = 85)
Age (years) 64.6±10.8 64.9± 10.8 64.0± 10.8 65.7± 10.9 0.421
Male (%) 404 (77.8) 139 (76.8) 199 (78.7) 66 (77.6) 0.899
Body mass index (kg/m2) 23.91±2.80 23.74± 2.90 24.11± 2.77 23.66± 2.89 0.267
Hypertension 334 (64.4) 118(65.2) 165 (65.2) 51 (60.0) 0.657
Diabetes 182 (35.1) 63 (34.8) 89 (35.2) 30 (35.3) 0.996
Smoking 240 (46.2) 77 (42.5) 121 (47.8) 42 (49.4) 0.450
Old myocardial infarction 103 (19.8) 42 (23.2) 42 (16.6) 19 (22.4) 0.193
CHOL (mmol/l) 4.27±1.33 4.19± 1.06 4.38± 1.54 4.15± 1.15 0.218
TG (mmol/l) 1.70±1.16 1.63± 1.01 1.75± 1.30 1.69± 1.00 0.576
HDL (mmol/l) 1.05±0.27 1.06± 0.27 1.04± 0.27 1.04± 0.27 0.772
LDL (mmol/l) 2.72±0.92 2.68± 0.95 2.77± 0.86 2.65± 1.04 0.456
CR (umol/l) 81.1±23.0 80.9± 20.8 81.8± 25.4 79.2± 19.5 0.649
PLT (×109) 217.8±60.6 214.1± 61.1 211.3± 58.4 216.3± 65.9 0.456
Fg (g/l) 3.56±1.02 3.53± 1.10 3.57± 0.97 3.58± 1.01 0.911
THERAPY AT DISCHARGE (%)
ACEI/ARB 425 (81.9) 147 (81.2) 213 (84.2) 65 (76.5) 0.267
Beta-blocker 447 (86.1) 156 (86.2) 221 (87.4) 70 (82.4) 0.514
CCB 119 (22.9) 42 (23.2) 54 (21.3) 23 (27.1) 0.552
Statins 519 (100) 181 (100) 253 (100) 85 (100)
PPI 519 (100) 181 (100) 253 (100) 85 (100)
Tirofiban 116 (22.4) 36 (19.9) 54 (21.3) 26 (30.6) 0.129
Naoxintong 171 (32.9) 58 (32.0) 80 (31.6) 33 (38.8) 0.450
PCI (%)
Left main coronary artery lesion 28 (5.4) 10 (5.5) 13 (5.1) 5 (5.9) 0.962
Vascular lesion ≥ 3 260 (50.1) 82 (45.3) 132 (52.2) 46 (54.1) 0.266
Bracket number 1 (1) 1 (1) 1 (1) 2 (1) 0.081
Frame length (mm) 33.0 (29.0) 33.0 (28.0) 38 (29.5) 38 (36.5) 0.064
Data are expressed as means ± SD or numbers (%). TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ACEI, angiotensin-converting enzyme inhibitor;
ARB, angiotension II receptor blocker; CCB, calcium channel blockers; PPI, proton pump inhibitor; CR, serum creatinine; PLT, platelet count; Fg, fibrinogen; EM, extensive metabolizers;
IM, intermediate metabolizers; PM, poor metabolizers.
using Kruskal-Wallis one-way analysis of variance (Table 2). All
the parameters examined showed a higher trend in PM than IM
patients. Comparison of these parameters in the EM and IM+PM
groups revealed significant differences (Table 2, Figure 2), with
higher levels in IM+PM than in EM patients (All P < 0.05).
Effects of CYP2C19 Metabolizers on
Clinical Outcomes
One-year follow-up was completed in 559 patients. The total
clinical outcomes are shown in Figure 3. During the follow-up
period, 69 patients (13.3%) experienced adverse cardiovascular
events (1 cardiac death, 9 myocardial infarction and 59 unstable
angina). The total frequency of MACE was different among EM,
IM and PM patient groups (7.8% vs. 17.8% vs. 11.8%, P= 0.009).
The frequency of unstable angina differed among EM, IM and
PM patients (6.6% vs. 15.4% vs. 9.8%, P = 0.014). We observed
a strong trend toward higher frequency of unstable angina and
MACE in IM patients, compared to PM patients. Comparison
of the total frequencies of MACE and unstable angina in EM
and IM+PM groups additionally revealed significant differences
(Table 3). MACE-free survival was further analyzed in patients
groups stratified by CYP2C19 metabolizer status. As shown in
Figure 4, CYP2C19 EM patients exhibited significantly lower
rates of MACE, compared with patients in the IM, PM, and
combined IM+PM groups.
Univariate and Multivariate Logistic
Regression Analysis of the Impact Factors
of MACE after PCI
Using MACE after PCI as the dependent variable and age,
BMI, CHD risk factors (hypertension, diabetes, smoking),
vascular lesions ≥ 3, frame length, bracket number, levels of
platelet activity indicators after PCI and CYP2C19 metabolizers
(IM+PM and EM) as independent variables, we analyzed
whether these relevant parameters influence the occurrence of
MACE. Univariate logistic regression analysis showed significant
association of CYP2C19 metabolizers with occurrence of MACE
(OR = 2.318 (1.251–4.297), P = 0.008) (Table 4). Multivariate
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TABLE 2 | Comparison of residual platelet reactivity, inflammatory, and endothelial biomarkers in clopidogrel-treated patients from various CYP2C19
metabolizer groups after PCI.
Parameters CYP2C19 metabolizers P-value* P-value#
EM (N = 181) IM (N = 253) PM (N = 85) IM+PM (N = 338)
RPA 8.58 (17.19) 15.89 (27.68) 23.39 (30.84) 17.53 (28.55) P < 0.001 P < 0.001
MAR 24.49 (24.82) 33.04 (29.54) 33.66 (38.11) 33.13 (30.48) P = 0.001 P < 0.001
sE-selectin (ng/ml) 5.98 (1.84) 7 (2) 7 (3) 7 (3) P < 0.001 P < 0.001
sCD40L (pg/ml) 7989.1 (4397.4) 8819.5 (4488.0) 8440.0 (5906.0) 8560.95 (4681.52) P = 0.001 P = 0.002
sP-selectin (ng/ml) 9.31 (5.99) 11.03 (6.08) 11.89 (6.89) 11.67 (6.12) P = 0.035 P < 0.001
MMP-9 (ng/ml) 178.11 (223.89) 361.34 (143.54) 348.38 (224.18) 357.22 (228.89) P < 0.001 P < 0.001
sVCAM-1 (ng/ml) 175.25 (133.16) 216.63 (106.77) 233.91 (112.19) 222.06 (111.29) P < 0.001 P < 0.001
Values are median (interquartile range). RPA, residual platelet aggregation rate; MAR, maximum platelet aggregation rate; EM, extensive metabolizers; IM, intermediate metabolizers;
PM, poor metabolizers. P-value*, Kruskal-Wallis one-way analysis comparing EM, IM and PM; P-value#, Mann-Whitney U-test comparing EM and IM+PM.
FIGURE 2 | Comparison of residual platelet aggregation indexes in patients stratified by CYP2C19 metabolizers after PCI. (A) RPA, (B) MAR, (C)
sE-selectin, (D) sP-selectin, (E) sCD40l, (F) MMP-9, and (G) sVCAM-1 between EM and IM+PM patients.
logistic regression analysis further disclosed that smoking,
frame length and CYP2C19 IM+PM genotypes are significantly
associated with risk of MACE (P = 0.008, P = 0.028, P =
0.004, respectively). Notably, the risk of MACE in CYP2C19
IM+PM patients was 2.664 times higher than that in CYP2C19
EM patients (OR= 2.664 (1.397–5.193), P = 0.004) (Table 5).
DISCUSSION
The current study focused on determining whether CYP2C19
genetic variants modulate clopidogrel-mediated antiplatelet
effects and risk of MACE in patients undergoing PCI. Our
main findings were as follows: (1) CYP2C19∗2 and ∗3 variants
influence RPA, MAR and levels of sE-selectin, sCD40L,
sP-selectin, MMP-9, and sVCAM-1 in patients following PCI.
The efficacy of clopidogrel is reduced in IM+PM, compared to
EM patients. (2) CYP2C19 EM patients have lower risk ofMACE,
compared with IM, PM, and IM+PM groups. (3) CYP2C19∗2
and ∗3 variants are independent risk factors of MACE in patients
undergoing PCI.
Several studies have consistently reported that the CYP2C19∗2
polymorphism is associated with lower antiplatelet response
and increases the rate of recurrent cardiovascular events in
Caucasian, Korean, and Chinese patients (Brandt et al., 2007;
Shuldiner et al., 2009; Hochholzer et al., 2010; Oh et al., 2012;
Liu et al., 2013). Moreover, the CYP2C19 ∗3 variant is associated
with clopidogrel-mediated antiplatelet effects, especially in Asia.
Since the incidence of the CYP2C19 ∗3 variant A allele is less
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than 1% in Caucasian populations, no carriers of CYP2C19 ∗3
were identified among 187 Caucasian healthy subjects and 237
Caucasian patients undergoing PCI in an earlier study (Geisler
et al., 2008; Shuldiner et al., 2009). Conversely, the frequency
of the CYP2C19 ∗3 variant in several Asian population studies
FIGURE 3 | One-year follow-up clinical outcome distributions of
clopidogrel-treated patients after PCI.
was significantly higher at >20% (Lee et al., 2009; Yamamoto
et al., 2011). Interestingly, CYP2C19∗17, another functional
variant, is additionally reported to contribute to the antiplatelet
effect of clopidogrel (Sibbing et al., 2010), but its frequency is
relatively rare (Chen et al., 2008; Sibbing et al., 2010). In the
current study, we defined EM, IM, and PM patients treated with
clopidogrel according to CYP2C19∗2 and ∗3 variant status to
reflect CYP2C19 enzymatic activity more comprehensively and
accurately.
To date, no large-scale clinical studies on clopidogrel
resistance have been conducted, mainly due to the lack of clear
and accepted definitions. Over several decades, the ADP-induced
optical turbidimetric platelet aggregation assay, the traditional
“gold standard” method to detect platelet function, has been
employed to evaluate the antiplatelet efficacy of clopidogrel.
However, in studies using this platelet function test, cutoff
values for high on-treatment platelet reactivity established via
receiver operating characteristic curve analysis were variable
(Palmerini et al., 2014). A number of studies used other
measures, such as SYNTAX score or platelet reactivity index,
to investigate associations with risk of mortality, myocardial
infarction and ST in patients with non–ST segment elevation
acute coronary syndrome undergoing PCI (Palmerini et al., 2011,
TABLE 3 | Comparisons of MACE among different CYP2C19 metabolizer patient groups.
Parameters CYP2C19 metabolizers P-value* P-value# OR (Odds ratio (95%CI))#
EM (N = 181) IM (N = 253) PM (N = 85) IM+PM (338)
Cardiac death 1 (0.6%) 0 0 0 0.392 0.354 –
Myocardial infarction 1 (0.6%) 6 (2.4%) 2 (2.4%) 8 (2.4%) 0.32 0.172 1.374 (1.081–1.746)
Unstable angina 12 (6.6%) 39 (15.4%) 8 (9.4%) 47 (13.9%) 0.014 0.013 1.259 (1.088–1.458)
Total 14 (7.8%) 45 (17.8%) 10 (11.8%) 55 (16.3%) 0.009 0.006 1.267 (1.1.3–1.456)
Abbreviations are the same as for Table 2. P-value*, Chi-square or Fisher exact test comparing EM, IM, and PM; P-value#, Chi-square or Fisher exact test comparing EM and IM+PM.
FIGURE 4 | MACE-free survival in patients stratified by CYP2C19 metabolizer status. (A) EM vs. IM vs. PM; (B) EM vs. IM+PM. Differences were compared
using the log-rank test.
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TABLE 4 | Univariate analysis of variables in relation to occurrence of
MACE after PCI.
Variables OR (95%CI) P-value
Age 1.073 0.645–1.785 0.787
BMI 1.011 0.924–1.106 0.825
Hypertension 0.785 0.467–1.317 0.359
DM 0.915 0.535–1.565 0.746
Smoking 1.006 0.605–1.673 0.981
Vascular lesion ≥ 3 1.347 0.808–2.245 0.253
Frame length (mm) 1.009 0.998–1.020 0.108
Bracket number 1.249 0.908–1.719 0.172
RPA 0.992 0.975–1.009 0.337
sCD40L 1 1.000–1.000 0.638
sP-selectin 0.991 0.956–1.028 0.633
MAR 1.001 0.987–1.015 0.911
MMP-9 1.001 1.000–1.001 0.05
sVCAM-1 1.001 1.001–1.003 0.116
sE-selectin 1.026 0.960–1.096 0.446
CYP2C19 metabolizers 2.318 1.251–4.297 0.008
Abbreviations as for Tables 1, 2.
TABLE 5 | Multivariate analyses of variables in relation to occurrence of
MACE after PCI.
Variables OR (95% CI) P-value
The number of coronary lesions 0.015 (0.687–2.172) 0.003
Smoking 0.958 (0.928–0.989) 0.008
Frame length (mm) 1.030 (1.003–1.058) 0.028
Bracket number 1.039 (0.575–1.878) 0.898
CYP2C19 metabolizers 2.664 (1.397–5.193) 0.004
Abbreviations as for Tables 1, 2.
2014). Clopidogrel blocks the platelet ADP receptor to inhibit
platelet aggregation, in turn reducing expression of sCD40L and
P-selectin and releasing them from platelets to prevent further
platelet activation (Blake and Ridker, 2001; Steinhubl et al., 2002;
Conde and Kleiman, 2003; Azar et al., 2006). Since the levels of
sCD40L and sP-selectin are significantly different between the
resting and activated states of platelets, they could be effectively
evaluated as markers of platelet activation. These indexes can also
be used for early assessment of the extent of platelet activation
and anti-platelet effects to avoid the occurrence of ischemic and
thrombotic events. We not only determined MAR and RPA,
but also sCD40L and P-selectin levels in patients undergoing
PCI after 24 h. Levels of these molecules were significantly
lower in EM than IM+PM patients, supporting the conclusion
that CYP2C19 metabolizers influence the anti-platelet effect of
clopidogrel.
ST and in-stent restenosis involve platelet activation,
inflammation and endothelial injury factor interactions.
Clopidogrel has unique anti-inflammatory effects and could
improve endothelial function (Ferroni et al., 2003; Heitzer et al.,
2006; Husted et al., 2010; Zhang et al., 2015). Accordingly,
we measured the levels of inflammation and endothelial
injury factors, such as MMP-9, sVCAM-1, and sE-selectin, in
patients undergoing PCI. Our results disclosed differences in
MMP-9, sVCAM-1 and sE-selectin contents among CYP2C19
variant groups. Specifically, MMP-9, sVCAM-1, and sE-selectin
levels were significantly higher in CYP2C19 IM and PM than
EM patients, implying that the CYP2C19 variants influence
the metabolic activity of clopidogrel, further affecting its
pharmacological ability to suppress inflammation and improve
endothelial function.
We followed up 559 patients undergoing PCI treated with
clopidogrel for 1 year, among which 519 were finally enrolled.
Our data revealed a higher percentage of MACE in CYP2C19
IM and PM than EM patients. Moreover, the risk of MACE
in IM+PM patients was 1.267 times higher than that in EM
patients. Univariate analysis consistently showed that CYP2C19
metabolizers influence the occurrence of MACE after PCI.
After adjustment for age, BMI, CHD risk factors (hypertension,
diabetes, smoking), vascular lesions ≥3, frame length, bracket
number and levels of platelet activity indicators (RPA, MAR,
sCD40L, P-selectin, MMP-9, sVCAM-1, and sE-selectin), data
from multivariate analysis showed that the risk of MACE in
IM+PM patients is 2.664 times higher than that in EM patients.
Our results are consistent with earlier studies showing that
CYP2C19 variants influence the risk of MACE in ACS or PCI
patients treated with clopidogrel (Sibbing et al., 2009; Mega
et al., 2010a; Wallentin et al., 2010; Jang et al., 2012). In
both univariate and multivariate analyses, we did not establish
platelet activity indicators or other inflammation and endothelial
injury factors related to the risk of MACE. Previous studies
have investigated sVCAM-1, E-selectin and other factors that
influence the prognosis of acute myocardial infarction patients.
The majority of subjects in our study were unstable angina
patients undergoing PCI. Since these factors were examined after
24 h of PCI, the detected levels may not reflect occurrence of
MACE, and further research is therefore required to establish
this issue. Moreover, during the follow-up period, our study was
limited to MACE data and did not include additional factors
that could have influenced survival-free analysis, such as liver or
kidney dysfunction.
Taken together, our results suggest that CYP2C19∗2 and ∗3
variants influence the levels of RPA, MAR, sE-selectin, sCD40L,
sP-selectin, MMP-9, and sVCAM-1 in coronary heart patients
undergoing PCI and modulate the drug efficacy of clopidogrel,
further increasing the risk of MACE. Based on these findings,
we propose that CYP2C19 pharmacogenetic profiling may be
beneficial for coronary heart patients undergoing PCI to predict
whether treatment with clopidogrel is a feasible option. IM
and PM patients may benefit from higher clopidigrel doses to
improve efficacy and reduce the incidence of MACE.
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